{"slug":"vip-semaglutide","verification":{"valid":true,"entries":2,"head":"3e5435625d4cf74722cb24031e294eb086f69af9de2172d13a7b3ee9f8b109fe"},"energy":{"passes":2,"tokens_in":14282,"tokens_out":3209,"tokens_total":17491,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"3e5435625d4cf74722cb24031e294eb086f69af9de2172d13a7b3ee9f8b109fe"},"provenance":[{"ts":"2026-06-29T22:19:42.479Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Vip for Semaglutide\nSlug: vip-semaglutide\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"dual_compound\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"vip\",\"name\":\"VIP\"},{\"id\":\"semaglutide\",\"name\":\"Semaglutide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"vip\",\"name\":\"VIP\",\"section_title\":\"Why VIP might help you\",\"layer\":\"immune / autonomic\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"},{\"peptide\":\"semaglutide\",\"name\":\"Semaglutide\",\"section_title\":\"Why Semaglutide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Weight-related joint and disc overload; metabolic stress on repair capacity.\",\"**What Semaglutide is studied to do:** Studied for GLP-1-driven weight loss — reduces mechanical load on weight-sensitive tissues.\",\"**Therefore for you:** If that layer is part of your problem, Semaglutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Weight-related joint and disc ov","response":"{\n  \"slug\": \"vip-semaglutide\",\n  \"title\": \"VIP and Semaglutide: Layered Evidence on Immune/Autonomic and Metabolic Repair Pathways\",\n  \"body\": \"## What's breaking down\\n\\nNo single condition profile is specified. Degeneration layers are inferred from the compound pairing and available evidence topology. Two distinct layers appear in the data: immune and autonomic signaling balance, and metabolic load from excess body weight that increases compressive forces on weight-bearing tissues.\\n\\nIf immune or autonomic regulation is part of the picture, breakdown shows up as cytokine imbalance or altered neuropeptide signaling. If metabolic load is present, excess weight adds roughly four pounds of lumbar compressive force for every extra pound carried, according to mechanical models referenced in weight-loss literature. This can outrun local repair capacity in discs, joints, and surrounding tissues. Semaglutide is studied for the second layer; VIP is discussed for the first.\\n\\n## Why VIP might help you\\n\\nVIP targets immune and autonomic layers. \\n\\n1. Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\\n\\nHuman data on inhaled VIP in primary pulmonary hypertension showed reduced mean pulmonary artery pressure and improved walk distance after 12–24 weeks (preclinical to small human series). Mechanistic work describes VIP shifting cytokine profiles toward regulatory T cells and lowering pro-inflammatory signals in cell and animal models of inflammation. No large randomized human trials exist for broad immune conditions. Associations appear in observational work linking higher VIP levels to lower anxiety/depression scores in one small cohort.\\n\\n## Why Semaglutide might help you\\n\\nSemaglutide targets metabolic load and body weight. \\n\\n1. What keeps failing: Weight-related joint and disc overload; metabolic stress on repair capacity.\\n2. What Semaglutide is studied to do: Studied for GLP-1","tokens_in":14282,"tokens_out":3209,"cost":0,"prev":"genesis","hash":"428645b8f08cc8c04be88ab109c3c1d2bcb9eebce9e1f4e3bc8a0b6ff6240d9c"},{"ts":"2026-07-17T02:43:27.137Z","model":"owner","action":"voxel_divide","prompt":"","input":"vip-semaglutide","response":"27 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"428645b8f08cc8c04be88ab109c3c1d2bcb9eebce9e1f4e3bc8a0b6ff6240d9c","hash":"3e5435625d4cf74722cb24031e294eb086f69af9de2172d13a7b3ee9f8b109fe"}]}